DISSOCIATION OF CARDIOSPECIFIC BIOMARKERS AND LEFT VENTRICULAR SYSTOLIC FUNCTION IN PATIENTS WITH ACUTE LEUKEMIAS
Keywords:
Acute leukemia, subclinical myocardial injury, cardiotoxicity, NT-proBNP, troponin T, ejection fraction, cardio-oncology.Abstract
Cardiovascular complications are a significant factor limiting the administration of antitumor therapy in patients with acute leukemias. Traditional assessment of cardiotoxicity is predominantly based on the dynamics of left ventricular ejection fraction (LVEF); however, functional myocardial changes may develop later than biochemical signs of damage. Elevation of cardiac troponin and NT-proBNP with preserved LVEF potentially reflects a subclinical stage of myocardial injury and may be used for earlier risk stratification.
References
1. Kayumov A.A., Zokirova M.B. Antioxidant defense gene polymorphisms as molecular genetic predictors of cardiotoxicity in patients with acute leukemia. Genetics and Molecular Research 25 (9s): 2026.
2. Kayumov A.A., Berger I.V., Mahamadalieva G.Z., et al. Cellular Therapy and Transplantation, 2024.
3. Muborakkhon Zokirova, Kayumov Abdurakhman, Nargiza Nurillaeva and Jakhongir Khaydarov. An Integrated Model of Cardiotoxicity: Interaction of Age, Sex, and Genetic Polymorphisms in Patients with Acute Leukemia. Biomedicines 2026, 14(9), 1929; https://doi.org/10.3390/biomedicines14091929 (registering DOI) - 28 Aug 2026.
4. Couch LS, López-Fernández T, Lyon AR. The 'Ten Commandments' for the 2022 European Society of Cardiology guidelines on cardio-oncology. Eur Heart J. 2023;44(1):10–11. doi:10.1093/eurheartj/ehac666.
5. Prevention of Cancer Therapy-Related Cardiac Dysfunction and Heart Failure in Cancer Patients and Survivors: a Clinical Consensus Statement of the Heart Failure Association, European Association of Preventive Cardiology and ESC Council of Cardio-Oncology. Eur J Heart Fail. 2025;27(11):2084–2113.
